• 1
    Alter M, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341: 55662.
  • 2
    Flamm S. Chronic hepatitis c virus infection. JAMA. 2003;289: 2413.
  • 3
    Fried MW, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347: 97582.
  • 4
    Lauer G, Walker B. Medical progress: hepatitis c virus infection. N Engl J Med. 2001;345: 41.
  • 5
    Manns MP, et al. Peginterferon-alpha2b plus ribavirin compared with interferon-alpha2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;348: 95865.
  • 6
    Cawthorne CH, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol. 2002;97: 14955.
    Direct Link:
  • 7
    Falck-Ytter Y, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136: 28892.
  • 8
    Yawn BP, et al. Identification and management of hepatitis C patients in primary care clinics. J Fam Pract. 2002;51: 13540.
  • 9
    Allen SA, et al. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138: 18790.
  • 10
    Backmund M, et al. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34: 18893.
  • 11
    Sylvestre D. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Dependence. 2002;67: 11723.
  • 12
    Thiel DHV, et al. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol. 1995;7: 1658.
  • 13
    Anonymous. Management of hepatitis c: 2002. NIH Consens State Sci Statements. 2002;19: 146.
  • 14
    Librero J, Peiro S, Ordinana R. Chronic comorbidity and outcomes of hospital care: length of stay, mortality, and readmission at 30 and 365 days. J Clin Epidemiol. 1999;52: 1719.
  • 15
    Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the US preventive services task force. Ann Intern Med. 2004;140: 46579.
  • 16
    USPSTF. Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med. 2004;140: 4624.
  • 17
    Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med. 2001;345: 2157.
  • 18
    Schiff E. The alcoholic patient with hepatitis C virus infection. Am J Med. 1999;107: 95S9S.
  • 19
    Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Dependence. 2001;61: 2115.
  • 20
    Bamberger JD, et al. Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health. 2000;90: 699701.
  • 21
    Smirnoff M, et al. Directly observed therapy in an inner city hospital. Int J Tuberc Lung Dis. 1998;2: 1349.
  • 22
    Anonymous. Management of hepatitis C. NIH Consens Statements. 1997;15: 141.
  • 23
    Edlin BR, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345: 2114.
  • 24
    McGinn T. How primary care enhances hepatitis C treatment (conference workshop). J Gen Intern Med. 2004;19: 11.
  • 25
    Strader DB. Understudied populations with hepatitis C. Hepatology. 2002;36: S22636.
  • 26
    Grant RW, et al. Impact of population management with direct physician feedback on care of patients with type 2 diabetes. Diabetes Care. 2003;26: 227580.